Frank Perabo

Frank Perabo is currently the Chief Executive Officer at Tachyon Therapeutics where Frank is leading the development of an epigenetic-targeting KDM-4 inhibitor in Oncology. Prior to this role, Frank served as the President of MAIA Biotechnology, Inc. and the Chief Medical Officer and Executive VP of Clinical Development at ESSA Pharma. With a strong background in the medical field, Frank has also held various leadership positions at companies such as Astellas Pharma and Barricade Therapeutics, Corp. throughout their career.